


WHAT IS CLAIMED IS:

1. A pharmaceutical composition for the treatment of a malignant disease or condition in a mammal, the composition comprising a pharmaceutically acceptable excipient and a therapeutically effective dose of a compound of the formula



where R_1 is independently H or lower alkyl of 1 to 6 carbons;

R_2 and R_3 are independently H, lower alkyl of 1 to 6 carbons, F, Cl, Br, I, alkoxy of 1 to 6 carbons, or fluoroalkoxy of 1 to 6 carbons;

m is an integer 0 to 3;

o is an integer 0 to 4;

n is 0-5;

Y is phenyl, naphthyl, or a heteroaryl group selected from a group consisting of pyridyl, thienyl, furyl, pyridazinyl, pyrimidinyl, pyrazinyl, oxazolyl, thiazolyl, or imidazolyl, and

B is $COOH$, a pharmaceutically acceptable salt thereof, $CONR_6R_7$ or $COOR_8$ where R_6 and R_7 independently are hydrogen or an alkyl group of 1 to 6 carbons and R_8 is alkyl of 1 to 6 carbons,


said composition being adapted to be used in combination with another chemotherapeutic agent effective for the treatment of the malignant disease or condition of the mammal.

1 2. A pharmaceutical composition in accordance with Claim 1 wherein
2 the chemotherapeutic agent effective for the treatment of the malignant
3 disease or condition of the mammal is interferon.

4 3. A pharmaceutical composition in accordance with Claim 2 adapted
5 for the treatment of breast cancer.

6 4. A pharmaceutical composition in accordance with Claim 2 adapted
7 for the treatment of leukemia.

8 5. A pharmaceutical composition in accordance with Claim 1 wherein
9 the compound has the formula




17 where R₁ is H or methyl, R₃ is H or methyl, and R*₈ is H, or lower
18 alkyl of 1 to 3 carbons, or a pharmaceutically acceptable salt of said
19 compound.

20 6. A pharmaceutical composition in accordance with Claim 5 wherein
21 the chemotherapeutic agent effective for the treatment of the malignant
22 disease or condition of the mammal is interferon.

23 7. A pharmaceutical composition in accordance with Claim 6 adapted
24 for the treatment of breast cancer.

25 8. A pharmaceutical composition in accordance with Claim 5 adapted
26 for the treatment of leukemia.

27 9. A pharmaceutical composition in accordance with Claim 1 wherein
28 the compound has the formula



where R_8 is H, alkyl of 1 to 3 carbons, or a pharmaceutically acceptable salt of said compound.


10. A pharmaceutical composition in accordance with Claim 9 wherein the chemotherapeutic agent effective for the treatment of the malignant disease or condition of the mammal is interferon.

11. A pharmaceutical composition in accordance with Claim 10 adapted for the treatment of breast cancer.

12. A pharmaceutical composition in accordance with Claim 10 adapted for the treatment of leukemia.

13. A pharmaceutical composition in accordance with Claim 9 where R_8 is ethyl.


14. A method of treating a malignant disease or condition in a mammal in need of such treatment, the method comprising the steps of:
administering to said mammal a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a therapeutically effective dose of a compound of the formula



Sub AB
cont.

0040852.031700

- 1 where R_1 is independently H or lower alkyl of 1 to 6 carbons;
2 R_2 and R_3 are independently H, lower alkyl of 1 to 6 carbons, F, Cl,
3 Br, I, alkoxy of 1 to 6 carbons, or fluoroalkoxy of 1 to 6 carbons;
4 m is an integer 0 to 3;
5 o is an integer 0 to 4;
6 n is 0-5;
7 Y is phenyl, naphthyl, or a heteroaryl group selected from a group
8 consisting of pyridyl, thienyl, furyl, pyridazinyl, pyrimidinyl, pyrazinyl;
9 oxazolyl, thiazolyl, or imidazolyl;
10 B is COOH, a pharmaceutically acceptable salt thereof, $CONR_6R_7$ or
11 $COOR_8$ where R_6 and R_7 independently are hydrogen or an alkyl group of 1
12 to 6 carbons and R_8 is alkyl of 1 to 6 carbons, and
13 co-administering to said mammal with said compound another
14 chemotherapeutic agent effective for the treatment of the malignant disease or
15 condition of the mammal.
16 15. A method in accordance with Claim 14 where the
17 chemotherapeutic agent is interferon.
18 16. A method in accordance with Claim 15 where the
19 chemotherapeutic agent is human recombinant interferon α , human
20 recombinant interferon β , or human recombinant interferon γ .
21 17. A method in accordance with Claim 16 where the malignant
22 disease or condition treated is breast cancer or leukemia.
23 18. A method in accordance with Claim 17 where the malignant
24 disease or condition treated is acute myeloid leukemia.
25 19. A method in accordance with Claim 14 wherein the compound has
26 the formula



where R_1 is H or methyl, R_3 is H or methyl, and R^*_8 is H, or lower alkyl of 1 to 3 carbons, or a pharmaceutically acceptable salt of said compound.


20. A method in accordance with Claim 19 where the chemotherapeutic agent is interferon.

21. A method in accordance with Claim 20 where the chemotherapeutic agent is human recombinant interferon α , human recombinant interferon β , or human recombinant interferon γ .

22. A method in accordance with Claim 21 where the malignant disease or condition treated is breast cancer or leukemia.

23. A method in accordance with Claim 21 where the malignant disease or condition treated is acute myeloid leukemia.

24. A method in accordance with Claim 14 wherein the compound has the formula



1 where R_8 is H, alkyl of 1 to 3 carbons, or a pharmaceutically acceptable
2 salt of said compound.

3 25. A method in accordance with Claim 24 where R_8 is ethyl.

4 26. A method in accordance with Claim 25 where the
5 chemotherapeutic agent is interferon.

6 27. A method in accordance with Claim 26 where the
7 chemotherapeutic agent is human recombinant interferon α , human
8 recombinant interferon β , or human recombinant interferon γ .

9 28. A method in accordance with Claim 27 where the malignant
10 disease or condition treated is breast cancer or leukemia.

11 29. A method in accordance with Claim 27 where the malignant
12 disease or condition treated is acute myeloid leukemia.

13 30. A method in accordance with any of the Claims 24 through 29
14 wherein a daily dose of approximately 50 mg to 500 mg of the compound is
15 administered to the mammal.

add B3

09640852-081700